| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
155.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.09 - $17.24 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
761,536 |
| Total Buy Value |
$0 |
$0 |
$0 |
$5,493,638 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
16 |
| Total Shares Sold |
14,727 |
14,727 |
327,800 |
635,093 |
| Total Sell Value |
$76,904 |
$76,904 |
$4,151,836 |
$6,068,455 |
| Total People Sold |
2 |
2 |
6 |
8 |
| Total Sell Transactions |
2 |
2 |
13 |
21 |
| End Date |
2025-02-06 |
2024-11-05 |
2024-05-07 |
2023-05-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2025-03-07 |
4 |
S |
$5.23 |
$56,536 |
D/D |
(10,810) |
202,721 |
|
25% |
|
| Rossi Michael J |
PRESIDENT & CEO |
• • – |
2025-03-07 |
4 |
S |
$5.20 |
$20,368 |
D/D |
(3,917) |
137,083 |
|
25% |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,500 |
52,100 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
213,531 |
|
- |
|
| Pfreundschuh Peter P. |
CFO and Treasurer |
• – – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
31,800 |
77,800 |
|
- |
|
| Larocca John |
SVP, General Counsel & Secry |
• – – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
21,500 |
21,500 |
|
- |
|
| Rossi Michael J |
PRESIDENT & CEO |
• • – |
2025-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
105,300 |
141,000 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-09-19 |
4 |
OE |
$4.38 |
$100,000 |
D/D |
22,831 |
181,531 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-09-16 |
4 |
S |
$12.97 |
$389,100 |
I/I |
(30,000) |
67,681 |
|
53% |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-09-13 |
4 |
S |
$13.47 |
$875,550 |
I/I |
(65,000) |
97,681 |
|
55% |
|
| Lund-Hansen Torben |
SVP & CHIEF TECHNICAL OFFICER |
• – – |
2024-08-28 |
4 |
S |
$15.37 |
$768,500 |
D/D |
(50,000) |
35,600 |
|
50% |
|
| Lund-Hansen Torben |
SVP & CHIEF TECHNICAL OFFICER |
• – – |
2024-08-28 |
4 |
OE |
$4.38 |
$219,000 |
D/D |
50,000 |
85,600 |
|
- |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2024-08-26 |
4 |
S |
$14.69 |
$73,450 |
D/D |
(5,000) |
30,600 |
|
46% |
|
| Pfreundschuh Peter P. |
CFO and Treasurer |
• – – |
2024-07-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
46,000 |
|
- |
|
| Tyagi Ashu |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
5,825 |
|
- |
|
| Tagliaferri Mary |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
8,155 |
|
- |
|
| Hamill Laura |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
5,825 |
|
- |
|
| Gill David N |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
5,825 |
|
- |
|
| Healy James |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
31,603 |
|
- |
|
| Wedell-Wedellsborg Johan |
Director |
– • • |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
5,825 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-06-11 |
4 |
S |
$12.00 |
$420,000 |
I/I |
(35,000) |
162,681 |
|
-21% |
|
| Ber Gerard |
Director |
– • – |
2024-06-10 |
4 |
S |
$12.00 |
$8,664 |
D/D |
(722) |
1,608 |
|
-20% |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-06-10 |
4 |
S |
$12.03 |
$421,050 |
I/I |
(35,000) |
197,681 |
|
-20% |
|
| Kruse Bo |
EVP, CFO, SECRY & TREAS. |
• – – |
2024-05-31 |
4 |
S |
$12.07 |
$378,648 |
D/D |
(31,371) |
210,877 |
|
-14% |
|
| Kruse Bo |
EVP, CFO, SECRY & TREAS. |
• – – |
2024-05-31 |
4 |
OE |
$2.00 |
$62,742 |
D/D |
31,371 |
242,248 |
|
- |
|
278 Records found
|
|
Page 1 of 12 |
|
|
0.02 (0.52%) 
